<DOC>
	<DOC>NCT02489981</DOC>
	<brief_summary>The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.</brief_summary>
	<brief_title>Specific Use-result Surveillance of Spiriva Respimat in Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Patients diagnosed with severe persistent bronchial asthma Patient aged &gt;= 15 years Patients who are naive to Spiriva Respimat and receive Spiriva Respimat for the first time for treatment of bronchial asthma on top of at least ICS (Inhaled corticosteroids) treatment. Exclusion criteria: Patients who have a contraindication to Spiriva Respimat defined in the package insert for Spiriva Respimat Patients who have been enrolled this study before.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>